Terminated PHASE3 NCT00450970

Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)

Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC) Previously Treated With Unlimited Cytotoxic Chemotherapy Regimen (SPERA)

Sponsor: Agennix

Conditions Prostate Cancer

Interventions Oral Satraplatin

Updated 8 times since 2017 Last updated: Aug 9, 2012 Started: Feb 28, 2007 Primary completion: Mar 31, 2009 Completion: Dec 31, 2009

A PHASE3 clinical study on Prostate Cancer, this trial is terminated or withdrawn. The trial is conducted by Agennix and has accumulated 8 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Apr 2022 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Apr 2022 [monthly]

Terminated PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Feb 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Agennix

Data source: Agennix

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amarillo, United States , Ames, United States , Anaheim, United States , Anchorage, United States , Athens, United States , Augusta, United States , Austin, United States , Baton Rouge, United States , Bay Shore, United States , Bethesda, United States and 98 more locations